Open access peer-reviewed chapter

Chronotherapy Advances in the Management of Chronic Neurological and Cardiovascular Diseases: Complex Interactions of Circadian Rhythm Environmental Inputs, Nutrition and Drug Administration and Their Impact on Human Health

Written By

Alina Crenguța Nicolae, Ion-Bogdan Dumitrescu, Camelia Cristina Diaconu, Mirela Elena Ritivoiu, Carmen Adella Sirbu and Cristina Manuela Drăgoi

Submitted: 16 March 2022 Reviewed: 04 August 2022 Published: 30 August 2022

DOI: 10.5772/intechopen.106950

From the Edited Volume

Circadian Rhythm - New Insights Into Physiological and Pathological Implications

Edited by Cristina Manuela Drăgoi, Alina Crenguța Nicolae and Ion-Bogdan Dumitrescu

Chapter metrics overview

161 Chapter Downloads

View Full Metrics

Abstract

New scientific evidence raises awareness concerning the human-specific interplay among primary environmental conditions, such as the light–dark cycle, activity–rest alternation, nutritional patterns, and their reflection on the physiological and pathological characteristics that are displayed uniquely by every individual. One of the critical aspects in the clinic is to understand the role of circadian rhythms as remarkable modulators of the biological effects of drugs and to aim for an optimal overlapping of the time of administration of medicines with the physiologic release of certain hormones, the time-dependent expression of genes, or the key-regulatory protein synthesis, which are all circadian-driven processes. The pharmacokinetics and pharmacodynamics profiles, as well as the possible drug interactions of neurotropic and cardiovascular agents, are intensely subjected to endogenous circadian rhythms, being essential to identify as much as possible the patients’ multiple risk factors, from age and gender to lifestyle elements imprinted by dietary features, sleep patterns, psychological stress, all the way to various other associated pathological conditions and their own genetic and epigenetic background. This review chapter will highlight the involvement of biological rhythms in physiologic processes and their impact on various pathological mechanisms, and will focus on the nutritional impact on the circadian homeostasis of the organism and neurologic and cardiovascular chronotherapy.

Keywords

  • biological rhythms
  • chronopharmacology
  • chronotherapy
  • chrononutrition
  • cardiovascular drugs
  • neurologic diseases
  • sleep disorders

1. Introduction

Chronopharmacology, in its broadest sense, is the science that studies drug effects according to the time of their administration. As the human organism portrays a set of biological rhythms, its response to drug administration depends on its particular conditions at the moment when the drug enters the system. Indeed, the existence of rhythmic variations in the body circumstances reflects in the response to drugs: chronopharmacology studies these phenomena by assessing the variations in the activity, toxicity, and kinetics of medicines. Chronotherapy is the application of chronopharmacology outcomes, whose aim is to improve the benefit/risk ratio of the drug by optimizing the time of administration [1, 2, 3].

Many physiological processes in the array of metabolic balance, hormones synthesis, and release and nevertheless the sleep–wake behavior, are regulated by the circadian clock system, being closely related to everyday environmental inputs, such as the light–dark cycle, food consumption, and drug administration [4].

Advertisement

2. Chronobiology’s importance from the perspective of human health

Chronopharmacology is a punctual aspect of chronobiology, reflecting the variations in the activity or toxicity of a therapeutic agent according to the time of administration, but it also studies the modifications of biological rhythms as the length of their cycle and time of their greatest and weakest intensity due to drugs. Its goal is to improve therapeutic efficacy and reduce unsolicited effects [1].

Relevant to metabolic activity, chronopharmacology allows to preserve or improve the health state, while associating circadian modifications in the digestive, hepatic, and endocrine systems with the exact time of the patient’s meals. Studies show that sleep disorders or jet lag can be treated with drugs due to their beneficial impact on the adjustment of the circadian system. The connection between food and the circadian clock system has recently been encompassed in the term chrononutrition (Figure 1) [5, 6].

Figure 1.

Illustration of chronopharmacological and chrononutritional interactions with human organism and behavior.

Advertisement

3. Human circadian rhythms, entrainment mechanisms, and major regulatory pathways

For humans, the most prevalent circadian rhythm is represented by the sleep–wake cycle, being at its turn in close relationship with the light–dark pattern, imprinted by environmental circumstances.

The central pivotal role in generating and maintaining basal circadian rhythms is played by the suprachiasmatic nucleus (SCN) located at the level of the anterior hypothalamus, which is the most important circadian pacemaker responsible for establishing the physiological cycles and nevertheless behavioral and endocrine circadian patterns displayed by human beings. The SCN function is highly important for daily rhythms that, when it is surgically removed, as has been experimentally performed in rodent studies, the animals lose their ability to temporally synchronize with the environment [3].

The accumulated forfeits of different harmful events resident at the level of SCN essentially encountered in end-stage neurodegenerative diseases, translate into losing the sense of time: patients are going to sleep during the day or are remaining in a wakeful state in the dark period, they are feeling permanently hungry or going to the toilet at random intervals during the day or night [7, 8].

At this level, a link is established between the outer world and the interior one, considering the mechanisms of entrainment of the organism by sensing the light signals and transposing them into temporal information, and regulatory patterns disseminated to all downstream effector organs, tissues, and cells. The circadian regulatory pathway has remarkable profound echoes, implementing changes even in time-dependent genes, which modulate the expression of protein synthesis, resetting all other biological clocks present in the pineal gland, the pituitary gland, or the adrenal gland. Besides light, there are different important zeitgebers that coordinate the hepatic or gastrointestinal tract clocks, mainly by the time of meals or by drug administration. The flexibility of these internal clocks is mandatory, in terms of connecting the SCN signals to the hunger and satiety center located also in the hypothalamus, instructing the relevant organs to act at the solicited time. After a desynchronizing event, the downstream reverberations are perceived slowly, but firmly, and the system resets itself within a few days, for example, midnight nutrients ingestion resets the gut and liver clocks in less than a week, aligning the metabolic machinery to the new consumption pattern [9, 10, 11, 12].

Advertisement

4. Phase shift modulation in the context of disruptive versus resynchronizing events

The human circadian structures are conceptualized in three distinctive components: a circadian oscillator with a rhythm of about 24 hours, pathways for the perception of light and other stimuli that synchronize the pacemaker with the environment, through zeitgebers, and effector systems and proper activities determined by SCN refinement. In humans, light is the dominant synchronizing agent for the internal clock, the photic information being conducted by direct and indirect pathways to the circadian system. In addition to the photic signal, the suppression of melatonin synthesis at the level of the pineal gland is a complementary mechanism implicated in conducting phase shifts in human circadian rhythms [12, 13].

The circadian shifts have an impact on activities including drug or nutrient absorption, distribution, metabolism, and excretion. Acknowledging these parameters when prescribing a drug and establishing the posology, dose and individual chemical characteristics, or the interactions with food intake can help improve human health and disease by increasing the potency of pharmacological and functional food effects. Secondly, just like light stimulation, drugs and food may be used to alter the phase of circadian clocks [14, 15, 16]. Internal clock disruptive events can occur simply by changing the timing of meals. Accordingly, the term chrononutrition also includes the following two elements: the involvement of food components and meal timing in the preservation of the health state and the role of food components in rapidly changing or reorganizing the endogenous clocks [10].

The importance of well-established nutritional routines, considering mainly the time of meals and the dietary habits, is highly acknowledged by all research studies in the field of nutrition. The reveal of the biochemical mechanism by which biological clocks are operating, namely the negative feedback regulation for the transcriptional process by means of binding Clock/Bmal1 to the E-box, was solid proof for pleading for stable eating habits. Circadian rhythms involve a clock regulated by negative transcriptional feedback. Clock/Bmal1, transcription factors, bind to E-box hexanucleotides to activate transcription of Per and Cry clock genes. The complex formed by Per and Cry inhibits its transcriptional activation by Clock/Bmal1. Subsequently, decreased activation of Per and Cry in turn causes transcriptional activation. This cycle takes approximately 24 hours. Although small gaps appear between cells, these gaps are adjusted by synchronizers [3, 17, 18].

This stability assures a certain equilibrium in the regulation of lipid metabolism, but more importantly, regulates the expression of the liver clock genes and the CYP7A1 isoform [4, 14, 16].

As such, chrononutrition will become a standard technique for maintaining our health via circadian rhythm system modulation. Knowing all the mechanistic details of food entrainment of the circadian clock will support the development of chrononutritional approaches for assuring nutritional optimal functionality.

Advertisement

5. The involvement of nutritional inputs and patterns in maintaining the circadian homeostasis of the organism

It is now understood that all cells have their own autonomous 24-hour clocks that work together as organ clocks, collectively forming a factor-integrated clock that synchronizes all organs. The rhythm of the digestive system is reversed when meal times are reversed, indicating that the digestive system clock synchronizer is sometimes stronger than the primary stimulus, namely light. It has been concluded by certain researchers that meals are among the strongest synchronizers for all organs and systems [19, 20].

The clocks of the organs cooperate to control the functions of the whole body, which can be defined as healthy. Experiments using mice with the clock gene removed show that its loss causes not only behavioral but also metabolic disorders. Experimental studies on circadian clock mutant mice exhibiting obesity or metabolic syndrome received much attention. In addition to arrhythmia, which was originally predicted, metabolic disorders in mice revealed that the circadian clock is strongly linked to peripheral metabolism [7, 21, 22]. On the other hand, there is a report of familial advanced sleep phase syndrome due to Per2 mutations in humans.

Gastric and intestinal digestion and absorption follow a circadian rhythm, being affected by clock genes rhythmically produced in the intestine and by the daily food intake (Figure 2). Extensive research has been conducted on the circadian expression of clock genes in the gastrointestinal tract. The obtained results revealed an advanced phase characteristic for the upper gut, being entrained faster than the lower gut, which is translated into a modification of the nutritional delivery rate at this level [17, 23].

Figure 2.

Circadian rhythmicity of nutrition-related processes regulators. AMPK, 5′ adenosine monophosphate-activated protein kinase; SIRT1, sirtuin 1 or silent mating type information regulation 2 homologue; PPAR, peroxisome proliferator-activated receptor; PGC1a, peroxisome proliferator-activated receptor gamma coactivator-1 alpha; Sglt1, sodium-dependent glucose cotransporter 1; Glut2, glucose transporter 2; Pept1, human peptide transporter 1.

The gastrointestinal system is subjected to a series of influence factors that are under tight circadian control, performed through genes exhibiting circadian patterns, which in their turn represent a signaling pathway. The most pronounced influence is driven by the nutritional schedule, being able to advance the idea of nutritional signaling. The colonic motility displays a clear rhythm, being active during the light period of the day and extremely silent during the night, the nitric oxide synthase activity and the clock genes regulating this cyclic process. The intestinal enzymes that perform the digestion of nutrients at this level have a circadian modulated activity timetable, which intimately follows the meal ingestion patterns, predicting the ideal time for synthesizing or activating these molecules. Consequent to this, the intestinal absorption of nutrients and xenobiotics registers a circadian fluctuation in close relationship with specific transporters’ expression [16, 17, 24].

The circadian system has an impact on food digestion, absorption, and metabolism. Furthermore, epithelial cell motility and proliferation in digestive compartments, particularly the colon, show diurnal rhythms. The absorption of glucose and water by the isolated small intestine is higher at night than during the day. The expression of sodium/glucose cotransporter 1 (Sglt1), glucose transporter 2 (Glut2), and glucose transporter 5 (Glut5) has clear circadian oscillations and is regulated by clock genes through E-box activity. Furthermore, PER1 activity regulates Sglt1 independently of the E-box. Following a scheduled feeding experiment, it has been concluded that feeding circumstances directly impact these transporters [9].

Food-derived phenolic compounds can interact with clock genes, which regulate the biological rhythms. In addition, nutrient signaling can affect gut circadian systems. Many important transporters are under circadian regulation, and circadian disruption also leads to abnormal drug absorption [22].

Advertisement

6. Circadian molecular mechanisms modulating the lipid metabolism

It is well known that changing the phase shift by night feeding leads to obesity, the main hypothesis states that the extra energy flow during the rest time is easily converted into lipids accumulation in the adipose tissue. In laboratory practice, it is common to use a high-fat diet to create an animal model of obesity [21, 22]. Although these phenomena are easy to understand, the molecular mechanisms are not fully elucidated.

Abnormalities in the body clock functioning, driven by a high-fat diet, are initiating the weight gain process in mice. This dietary habit also changes the liver clock and the hepatic rhythmicity of lipid metabolism. The influence of meal timing on lipid metabolism is not considered highly significant, while the importance of well-regulated eating habits is recognized [9]. Therefore, the influence of meal timing was examined using genetically unmodified animals. A feeding protocol was developed in which animals ate continuously regardless of time; although restricted feeding (e.g., feeding only during the day) causes day/night reversal in nocturnal rats, they become accustomed to it. It was reported that irregular meals cause abnormalities in the liver circadian clock and increase blood cholesterol levels. It was indicated that differences in meal timing cause abnormalities in cholesterol metabolism, even if the same quantity of food is provided [25]. Hypercholesterolemia was caused by advanced changes in the circadian rhythm and gene expression of CYP7A1, an isoenzyme that limits the rate of bile acid synthesis. Thus, cholesterol metabolism was profoundly altered and bile acid levels excreted decreased. These results indicate that well-regulated dietary habits normalize the liver clock gene and regulate the CYP7A1 rhythm and that blood cholesterol levels are better controlled due to a lower secretion of VLDL (very low-density lipoprotein), namely lowering LDL-cholesterol and raising HDL-cholesterol levels [19].

Advertisement

7. Expanding the perspective of the interplay between chrononutrition and chronotherapy

Time-restricted feeding, a nutritional approach in which food consumption is limited to certain times of the day, allows a daily fasting period of 12 hours or more, thus conferring metabolic resting-frames used by the cellular machinery to initiate and develop complex processes of repair, decreasing the level of accumulated errors due to oxidative stress injuries or aberrant mutations. Understanding the link between time, nutrients, and the benefits of fasting leads to the identification of chrononutritional strategies that mimic fasting and achieve similar changes to those triggered by fasting [3].

Acknowledging the pervasive and constant benefits of time-restricted feeding and fast-mimicking diets, basic science and translational research are willing to transform time-managed fasting-related interventions into complex clinical approaches with a remarkable potential to improve human health.

In the clinical scenery, an accurate identification must be performed for all interactions among drugs, drugs and food supplements, drugs and food and, nevertheless, drugs and genetic and epigenetic factors, all being able to impact the therapeutic outcome considerably. The absorption, distribution, metabolism, and elimination of drugs can be highly influenced by slight variations of the environmental factors and endogenous elements, mainly affecting their bioavailability, efficacy, and metabolism to toxic compounds [26].

The most exposed to this phenomenon are neurologic and cardiovascular patients due to the complexity of their pathology and the particularities of these anatomic and physiologic systems. Restricted scheduled food intake in experimental models determines the occurrence of food anticipatory activity in animals, which is observed approximately 2 hours before the feeding time. The learning process of specific times of feeding is acquired by the internal food-entrainable oscillator mechanism and this food-dependent entraining also encompasses clock gene expression rhythms in major cerebral and peripheral tissues, except the SCN. Several experimental studies demonstrated that by scheduled feeding, the animals depicted Per1, Per2, D-site-binding protein, and cholesterol 7 alpha-hydroxylase mRNA expression rhythms that underwent rapid phase shifting and entrainment at the hepatic level, and a slower rate in kidneys, heart, and pancreas and did not undergo at all scheduled feedings-phase shifting in the SCN [3, 5].

Regarding antihypertensive and neurotropic drugs, when evaluating their therapeutic efficacy, we have to equally consider the time of administration, their precise dose, and eventual matrix effects that can completely change their bioavailability profile. This is mainly due to their direct interdependence with biological rhythms, blood pressure physiologic oscillation during 24 hours, and nevertheless the circadian rate of metabolism at the hepatic level. The nutritional impact can also be displayed by food constituents that have additive or antagonist effects such as phenolic compounds and peptides, in conjunction with blood pressure levels [27].

Chronotherapeutic-chrononutritional studies conducted by Matsunaga et al. are of unique relevance in this field assessing the circadian pattern of hepatotoxicity and mortality rates after acetaminophen administration in mice subjected to ad libitum versus time-restricted feeding patterns, and food-entrained circadian rhythms modulated toxic effects through CYP2E1 and hepatic glutathione activities [28]. Analogous employments of food timing patterns on the chrono-pharmacokinetics were described in the activity of sodium valproate and the nephrotoxicity of gentamicin [29, 30].

Insulin signaling is one of the most important factors for food entrainment, as it directly induces Per2 expression in hepatic tissue and cultured hepatocytes [31]. AMPK, a fundamental cellular energy sensor, is another possible factor for food entrainment, being activated by fasting or low glucose levels. It undergoes phosphorylation and destabilizes CRY1 protein. Nutritional ingredients such as caffeine, an antagonist of the adenosine receptors and an inhibitor of phosphodiesterase, increasing cAMP concentrations, can lead to considerable changes in the circadian system as it was reported to lengthen the circadian clock period in the SCN and peripheral tissues and modulates the behavioral rhythms [32]. Functional nutrition may soon become an increasing topic of relevance in future chronotherapeutic strategies.

In most animal species as in humans, the feeding frames alternate with fasting frames. This specific metabolic picture is predominantly dependent on ketone bodies after a prolonged fasting time, glucose, and glycogen being consumed in the first fragment of the fast. Based on this restricted availability of glucose at the cellular level, many hypotheses were formulated to understand the great impact of fasting in preventing a series of metabolic imbalances and also in accompanying the treatment of chronic diseases, mainly cardiovascular, inflammatory, and oncological ones [16, 25, 33, 34].

Advertisement

8. Chronotherapeutic approaches: recognizing the importance of timing factors in the treatment of neurological diseases and sleep disorders

The suprachiasmatic nucleus (SCN) acquires valuable information from the environment, through input signals, such as the light–dark cycle, and nevertheless from other brain areas. There are several important chemical structures that were studied for their influence on the circadian entrainment mechanism of SCN, namely exogenous melatonin and ramelteon, a powerful selective melatonin MT1/MT2 receptor agonist. When administered during the active phase, they act as non-photic trainers that advance SCN circadian rhythms [35, 36, 37].

The field of neurology is an extremely complex one, reuniting a series of chronic neurological disabilities from insomnia, epilepsy, and neuromuscular disorders to degenerative diseases, dementia and brain tumors. As a highly prevalent and neurologic imbalance promoting affection, insomnia is affecting more than 30% of the general population, the sleep disturbances being a consequence of stressful life conditions, shift working, physiological aging, but nevertheless being the first clinical sign of a neurologic impairment stage. Its intimate connection with circadian misalignment is undoubtedly approved, addressing an interesting scientific intersection point in chronopharmacology [38, 39, 40].

The barbiturates, namely phenobarbital, were among the first-generation drugs used for insomnia, but due to their high abuse potential and associated risks of overdosing, were replaced by benzodiazepines (lorazepam and triazolam).

This second generation of hypnotics displayed different side effects in the area of cognitive and psychomotor impairment, displaying also phenomena of addiction and tolerance, urging the need for a different therapeutic approach. Benzodiazepine receptor agonists (zolpidem and zopiclone) represented the following generation of hypnotics having non-benzodiazepine chemical structures and exhibiting reduced side effects. After extensive clinical studies, it was concluded that the major drawback of this class was that the sleep induced by these pharmacologic agents is electrophysiologically different from the naturally prompted physiological sleep, as they are severely reducing the rapid eye movement (REM) phases of sleep [7, 41].

Melatonin, the pineal hormone discovered in 1958, is the major endogenous regulator of sleep–wake cycles, its synthesis being initiated by the diminishing photic signal, at sunset, and being stopped upon sensing the first light signal. The pineal synthesis pathway includes the essential amino acid tryptophan and most importantly the neurotransmitter serotonin. It has exceptional characteristics, being highly soluble in lipid medium, simply diffusing through almost every cellular membrane, including the blood–brain barrier, the ultimate frontier for most molecules, even the endogenous ones [13, 36, 42].

The half-life of melatonin is extremely short, around 30 minutes, being immediately enzymatically transformed in a series of metabolites, with particular functions in the oxidative stress array, in order to be finally converted by the liver and then urinary excreted. No other endogenous molecule shares the same unique strong circadian pattern of synthesis in healthy human organisms: the plasma level is detectable immediately after sunset, registering a peak around 3 a.m. and becomes untraceable in the early morning, a period superposable with the light signal initiation [43].

The intimate connection between melatonin and the utmost central nervous system structures is achieved through the specific receptors which are found in high densities in circadian regulatory entities, and in fact, to a certain extent, in most human organs. It is by this mechanism that it is understood the role of melatonin as a master hormone, endogenous synchronizer, and circadian modulator of all biological internal systems. Melatonin mediates the information regarding the dark signals throughout the entire body, conducting chronobiotic and phase shift effects, hypnotic by imprinting sleep–wake robust cycles, but at the same time, having a versatile modulatory ability to adjust the circadian pattern in disruptive circumstances [35].

Considered the initiator and maintainer of sleep in humans, the darkness hormone has proved its sleep-inducing effects only concerning the endogenous molecule, as the exogenous supplementation has resulted in controversial conclusions, mainly due to its short half-life, increased first-pass metabolism, and weak receptors binding. As the major non-photic entrainer of the circadian rhythm, exogenous melatonin is a powerful pharmacologic tool in correcting circadian misalignments in patients [44].

Melatonin was subjected lately to modern pharmaceutical formulations that assure better bioavailability characteristics that were efficient for inducing sleep and increasing the quality and length of sleeping time in elderly patients suffering from chronic insomnia, as it is acknowledged that the endogenous melatonin synthesis declines physiologically by aging, due to pineal gland calcification, decreased sensing of the light signal, or a decline in the SCN function [21].

Chronopharmacological approaches are of remarkable importance for a chronobiotic agent such as melatonin. A series of experimental and clinical studies have assessed the relationship between the administered melatonin dose, the time of administration, and the occurrence of biological effects and their intensity, in a plethora of circadian rhythm-derived sleep disorders, from a jet lag sleep disorder, shift work sleep disorder, delayed sleep phase syndrome, primary insomnia occurring in various psychiatric illness. The conclusions are unanimous stating that the time of the day used for administering exogenous melatonin is indisputably determining the precise effect on the circadian rhythms: delaying them after the morning administration, and on the contrary, advancing the circadian phase and subsequent evening sleep induction, following a late afternoon or night drug administration [40, 45].

Based on the clinical data, but mostly on the evidence suggesting the tremendous therapeutic effect displayed upon selectively binding the melatoninergic receptors, the MT1/MT2 agonist ramelteon was assessed for its role in circadian re-entrainment and for inducing sleep in refractory insomnia. The time of administration is also an important issue, taken into consideration by Watanabe et al. study, which concluded on the efficiency of small doses of 1–2 mg taken at more than 5 hours before bedtime, assumed as an early administration pattern [46]. In the vast majority of the performed trials, ramelteon proved good effects, especially on refractory insomnia cases, often combined with serious disturbances in circadian rhythms of sleep–wake cycles. All scientific data indicate that ramelteon acts not only as a hypnotic agent but also at a molecular level it is mimicking all central effects of melatonin as a circadian entrainer [37, 47, 48].

Numerous other central nervous system-acting drugs are of utmost chronotherapeutic importance due to their particular pharmacologic patterns in connection with their time of administration. For instance, the night-time administration of benzodiazepines down-regulates the expression of Per1 and Per2 genes, having a direct impact on the entrainment process at the level of SCN. Lithium, a classic mood stabilizer prescribed in manic episodes associated with bipolar disorder, inhibits glycogen synthase kinase-3 (GSK-3) in the suprachiasmatic nucleus, increasing the locomotor activity cycle [44, 49]. Anesthetic agents significantly influence circadian rhythms, causing either phase shifts, or diminishing the rhythmic amplitude of clock gene expression. Many central nervous system drugs, when administered together, can affect circadian rhythm via their target receptors and metabolism enzymes [2].

Advertisement

9. Current understandings and future directions in the chronopharmacology management of cardiovascular chronic diseases

Circadian rhythms have tremendous importance in cardiovascular system functions in both healthy people and patients, being one of the first scientifically acknowledged physiopathologic areas interlinked by chronomodulatory mechanisms [25]. Heart rate and blood pressure (BP) rhythms are the most studied periodic functions in the circulatory system, but lately, new evidence suggests blood flow, cardiac output, stroke volume, or peripheral resistance can furthermore trigger relevant circadian changes [50, 51].

Hypertension, the high systemic blood pressure, represents the major risk factor for a series of acute or chronic pathologic events, from myocardial infarction and ischemic events to chronic kidney failure and sudden death. Chronic high blood pressure is a silent condition since it progresses primarily asymptomatically, but has a devastating effect, conducting to cardiovascular disruptive events and end-organ damage, which leads to a reduction in the quality of life or events of life expectancy. The simple association between high blood pressure and cardiovascular diseases, which is largely controlled by our social and nutritional behavior, is also influenced by a circadian pattern. As a consequence, circadian rhythm plays an important role in blood pressure management, which is the reason for chronobiological studies to comprise chronopharmacology and chrononutrition aspects in the same research field [24, 52, 53].

Blood pressure registers circadian variations due to internal and external modulatory factors. Endogenous regulatory performers such as hematological and renal inputs, endocrine signals perceived by the circulatory system, and the autonomic nervous system activity, interact with environmental parameters like temperature and humidity, nutrients intake, vasoactive xenobiotics as alcohol and caffeine, and nevertheless with the physical activity, emotional status, and the sleep pattern. Despite the overabundance of parameters that influence it, circadian variations of blood pressure in normotensive patients are characterized by a decrease in both systolic and diastolic blood pressure during the night, on average by 10–20% compared with diurnal values, defining the normal pressure physiological profile [20, 33].

The magnitude of the decrease in nocturnal BP values was mainly quantified by calculating the dipping index (relative nocturnal decrease in BP) which is defined as the percentage decrease in the value of the average night BP compared with the mean daily BP. This dipping index allowed the classification of the night profile of TA in dipper profile when the index is between 10 and 20%, non-dipper profile when the night decrease of TA is less than 10%, of extreme-dipper type when the decrease of nocturnal BP is over 20% of daytime values and riser profile when BP increases during sleep. The classification has acquired a great utility, especially from the point of view of the prognosis, especially since there are studies that demonstrate the reproducibility of the evolution of nocturnal values of BP, in the same individual, for several months [51].

The circadian rhythm of BP shows maximum values in the early hours of the morning, followed by a subsequent gradual decrease and with minimum nocturnal values, respectively. Explanations of this variability involve the influence of exogenous or environmental factors and endogenous factors.

The endogenous rhythm associated with the body’s clock determines amplitudes ranging from 5 to 10 mmHg. Blood pressure increases adjacent to waking time are associated with increases in catecholamine plasma levels: both norepinephrine and epinephrine are at peak levels in the morning and low levels at night [33]. At the moment, there are many drug classes that are used in the management of hypertension, the majority of therapeutic schemes comprising a combination of them, as they have different mechanisms of action and sometimes variable sites of action, being complementary: α- and β-adrenoceptor blocking drugs, calcium channel blockers, diuretics, angiotensin-converting enzyme (ACE) inhibitors, AT1-receptor blockers, etc. (Figure 3). Ambulatory blood pressure monitoring of hypertensive patients is of absolute importance as it can reveal abnormal variable patterns predicting super dipping and late-night angina crises [54, 55].

Figure 3.

The biological mechanisms of blood pressure (BP) and the therapeutic approaches that are subjected to circadian modulation. α1 ADR.ANT, α1-adrenoreceptor antagonists; β ADR.ANT, β-adrenoreceptor antagonists; ACE.INH, ACE inhibitors; ALDO.ANT, aldosterone antagonists; AT1-REC.ANT, AT1-receptor antagonists; CAL.CH.BL, calcium channel blockers; DIUR, diuretics; REN.INH, renin inhibitors; RES, reserpine; VASODIL, vasodilators.

Furthermore, the pharmacokinetic profile, half-life, formulation, duration of pharmacological impact, and hence the dosing interval vary between antihypertensive medication classes and individual compounds.

The primary steps in the processes that regulate blood pressure are reliant on the circadian phase, indicating that β-adrenoceptor antagonists have no effect on, diminish, or even abolish the rhythmic pattern in BP. β-adrenoceptor antagonists, on the other hand, have the property to reduce daytime BP levels and have little effect on night-time values, being not effective in lowering the early morning spike in BP. Heart rate declines caused by β-adrenoceptor antagonists are consistently more evident during the daytime hours [24, 56].

Taking into account numerous studies conducted conventionally, β-adrenoceptor antagonists—β1-selective, nonselective, or with intrinsic sympathomimetic activity do not modify or lessen the rhythmic pattern in blood pressure. Generally, it is estimated that adrenoceptor antagonists lower daytime blood pressure levels while having little or no effect on nocturnal values and are less effective in reducing the early morning escalation in blood pressure levels [56].

The effects of β-adrenoceptor antagonists on heart rate are consistently more evident during the daytime. Correspondingly, a fourfold crossover trial using propranolol in healthy adults revealed a more dramatic reduction in heart rate and blood pressure during the day than at night. Furthermore, it is demonstrated that the circadian phase can affect the dose–response relationship. Pindolol, a partial agonist, even raised the heart rate at night, which was a surprising finding [26, 34]. Thus, clinical evidence suggests that β-adrenoceptor-mediated blood pressure regulation is more important during the day and less important at night and early in the morning. This is consistent with the circadian regularity in sympathetic tone, as evidenced by plasma noradrenaline and cAMP levels [56].

Calcium channel blockers’ effects were also investigated, primarily by the assessment of blood pressure profiles. The administration of non-retard verapamil three times a day did not significantly modify the blood pressure profile in primary hypertensive patients, however, it was less effective at night. A single morning dose of sustained-release verapamil provided good 24-hour blood pressure management, while a sustained-release diltiazem formulation was less effective at night [26, 52]. Different pharmacokinetics of dihydropyridine derivatives appear to decrease blood pressure to wide-ranging degrees during the day and night, the specific drug formulation, and dose interval play a role [27].

In essential hypertensive patients (dippers), amlodipine, sustained-release isradipine and lacidipine, nifedipine gastrointestinal therapeutic system (GITS), and nisoldipine extended-release (ER), as well as in normotensives, immediate-release nifedipine had no impact on the 24-hour blood pressure profile after one dose taken in the morning and one in the evening, whereas, with nitrendipine, there was either no impact or a slight impact after the evening dose. Nifedipine, taken twice a day, reduced blood pressure over a 24-hour period in primary hypertension individuals. Most notably, isradipine only normalized the greatly disturbed blood pressure profile in secondary hypertensives (non-dippers) due to renal failure after the evening, but not the morning dosing. In contrast, amlodipine and nisoldipine ER normalized the disturbed blood pressure profile in non-dippers after both morning and evening dosing [20].

These studies clearly show that calcium channel blockers lower elevated blood pressure in both non-dippers and dippers without distorting the latter’s normal blood pressure profile or causing super dipping and can convert non-dipping behavior into dipping behavior, the dose administered in the evening being more appropriate.

Several crossover studies, assessing morning versus evening dose, with ACE inhibitors in essential hypertensive patients, revealed that among dipper patients, the evening dosing of benazepril, enalapril, and perindopril resulted in a more dramatic overnight decline than the morning dose, resulting in a super dipping blood pressure profile. Evening quinapril doses had a stronger effect than the morning ones, but the blood pressure pattern was not significantly altered [57].

After either dosing time, ramipril had no visible effect on the 24-hour blood pressure profile. An excessively severe nocturnal reduction in blood pressure, the super dipping pattern, following night-time dosage could be a possible risk factor for the development of ischemic events in individuals with hypertension, given their reduced cardiac reserve.

Other antihypertensive agents have been seldom explored in regard to probable circadian fluctuations. In essential hypertensive patients, once-daily morning doses of the diuretics xipamide and indapamide decreased blood pressure without affecting its 24-hour pattern [58].

Trials conducted on diuretics in salt-sensitive hypertensive patients (dippers and non-dippers), revealed that diuretics did not modify the circadian blood pressure profile in dippers, but did turn non-dippers into dippers [20, 27, 33].

The α-adrenoceptor antagonists indoramin and prazosin did not modify the blood pressure profile when administered twice daily. Throughout both day and night, a single night-time dose of the α-adrenoceptor antagonist doxazosin lowered equally systolic and diastolic blood pressure, however, the greatest decrease occurred in the morning hours. Recent research in dippers using doxazosin-gastrointestinal therapeutic system (GITS) as monotherapy demonstrated a slight but considerable reduction in blood pressure over the course of 24 hours without disrupting the normal blood pressure profile. These findings suggest the importance of α-adrenoceptor mediated BP regulation during the early morning hours because α-adrenoceptor blockade lowered peripheral resistance more efficiently during the early morning hours than at other times of the day.

The capacity of the night/day ratio of systolic BP to predict the risk of cardiovascular events is more accurate than BP recorded once, according to studies conducted in recent years. Given that nocturnal blood pressures are most consistently associated with cardiovascular risk, they require closer monitoring for patient safety [53]. The circadian rhythm plays an important role in the regulation of blood pressure, and research conclusions suggest that time is one of the most important factors influencing cardiovascular risk management. As a result, chronopharmacotherapy is required for circadian disorders including hypertension.

It is obvious that circadian rhythms have a significant impact on cardiovascular disorders. Metabolic pathways, signal transduction cascades, transcriptional networks, protein turnover, and other processes are all timed to promote optimal cellular and organ functioning.

The disruption of the circadian governance almost always triggers pathology. In addition, it is more and more obvious that the persistence and augmentation of circadian rhythms might cause and aggravate CVD in vulnerable individuals. For that purpose, it is important to identify all the details regarding the mechanisms implied by the entrainment of the cardiovascular system, using the pattern of cell-to-cell synchronization, and the particular points where the phase misalignment is transformed into pathological events (Figure 4).

Figure 4.

The circadian imprint upon physiologic endocrine and metabolic parameters often reflected in the pathologic scenery of the human organism.

By gathering as much chronobiologic data as possible for a single patient, it is conceivable to develop therapeutic strategies that specifically target circadian clock components and downstream mediators for the effective treatment and prevention of cardiovascular diseases, to adjust some significant lifestyle behaviors, as the timing of eating, of performing exercise and environmental conditions, as the exposure to light and certain temperatures, that work in synchrony with circadian governance of cellular processes [2, 53].

Food and Drug Administration recommends that the vast majority of long-acting formulations are preferable to be administered in the evening, at bedtime. Exceptions are represented beta-blockers that are not specifically designed for chronotherapy or do not have a similar 24-hour effect from the point of view of heart rate reduction making sense to administer them in the morning when the sympathetic drive is predominant, diuretics have the same effect over 24 hours, but the discomfort from frequent night-time awakenings should be avoided. In addition, quinapril at doses of 30–40 mg may register an excessive effect and doxazosin may provide an excessive decrease when administered in the evening. There are indications for the administration of antihypertensive drugs early in the morning, for the dipper patients, and for the non-dippers, it is necessary to add an evening dose or to switch to a single evening dose, in order to acquire a reduction in the blood pressure levels and a normalization of the 24-hour profile that is profoundly disturbed in these patients [33]. As cardiovascular drugs have vulnerable pharmacokinetic profiles that can be easily influenced by the circadian phase, it is of great importance to consider the half-life of the active components and the exact parameters of the employed pharmaceutical formulation, in order to emit a sustainable conclusion regarding the best dosage time within 24 hours [15, 26].

All the data converge to show that for the “non-dipper” type of patients and for “extreme dippers” the cardiovascular prognosis is rather poor. However, the only way to positively influence these unfavorable types of circadian variability of BP values can only be achieved by chronotherapy. It offers a way to personalize the treatment of hypertension considering each patient’s distinct circadian profile, providing a better perspective on optimal blood pressure control and decreasing the associated cardiovascular risk.

It must be acknowledged that the development of antihypertensive therapy provides an effective arsenal in the sense of chronotherapy: the evolution from short-acting drugs to drugs that release the active substance slowly, allowing them to be administered in such a way as to achieve maximum effectiveness, both in terms of ideal day-time blood pressure values and by inducing a dipper-like profile of circadian variability during night-time.

Advertisement

10. Conclusions

In essence, food intake performs a strong entrainable role in regard to human circadian rhythms. In addition, this entrainment modulates the timing of food digestion and metabolism by controlling clock-regulated output genes in the peripheral tissues, having tremendous effects on drug bioavailability and metabolism.

Understanding the mechanisms of food entrainment in the circadian system and the complexity of nutritional signals will contribute to chrono-nutritional therapy guidelines concerning the joint functionality of food and nutrition.

In the next period of time, further research will completely elucidate the interactions along the remarkable time–nutrition–drug axis within the framework of chrononutrition modulated chronopharmacotherapy, becoming an essential tool for chronic pathologies management, by individualizing the chrono-pharmaco-therapeutic approach for every single patient.

References

  1. 1. Lemmer B, Portaluppi F. Chronopharmacology of cardiovascular diseases. In: Redfern P, Lemmer B, editors. Handbook of Experimental Pharmacology, Physiology and pharmacology of biological rhythms. Vol. 125. New York: Springer; 1997. pp. 251-297
  2. 2. Dobrek L. Chronopharmacology in therapeutic drug monitoring—dependencies between the rhythmics of pharmacokinetic processes and drug concentration in blood. Pharmaceutics. 2021;13(11):1915. DOI: 10.3390/pharmaceutics13111915
  3. 3. Tahara Y, Shibata S. Chrono-biology, chrono-pharmacology, and chrono-nutrition. Journal of Pharmacological Sciences. 2014;124(3):320-335. DOI: 10.1254/jphs.13r06cr
  4. 4. Dragoi CM, Morosan E, Dumitrescu IB, Nicolae AC, Arsene AL, Draganescu D, et al. Insights into chrononutrition: The innermost interplay amongst nutrition, metabolism and the circadian clock, in the context of epigenetic reprogramming. Farmácia. 2019;67:557-571
  5. 5. Gloston GF, Yoo SH, Chen ZJ. Clock-enhancing small molecules and potential applications in chronic diseases and aging. Frontiers in Neurology. 2017;8:100
  6. 6. Musiek ES, Holtzman DM. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 2016;354:1004-1008
  7. 7. Fifel K, Videnovic A. Circadian alterations in patients with neurodegenerative diseases: Neuropathological basis of underlying network mechanisms. Neurobiology of Disease. 2020;144:105029
  8. 8. Sion B, Bégou M. Can chronopharmacology improve the therapeutic management of neurological diseases? Fundamental & Clinical Pharmacology. 2021;35:564-581
  9. 9. Ahmed N, Farooq J, Siddiqi HS, Meo SA, Kulsoom B, Laghari AH, et al. Impact of intermittent fasting on lipid profile—A quasi-randomized clinical trial. Frontiers in Nutrition. 2021;7:596787
  10. 10. Scheving LA. Biological clocks and the digestive system. Gastroenterology. 2000;119:536-549
  11. 11. Voiculescu SE, Le Duc D, Roșca AE, Zeca V, Chiţimuș DM, Arsene AL, et al. Behavioral and molecular effects of prenatal continuous light exposure in the adult rat. Brain Research. 2016;1650:51-59
  12. 12. Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. British Journal of Pharmacology. 2018;175:3190-3199
  13. 13. Pevet P, Challet E. Melatonin: Both master clock output and internal time-giver in the circadian clocks network. Journal of Physiology, Paris. 2011;105:170-182
  14. 14. Bron R, Furness JB. Rhythm of digestion: Keeping time in the gastrointestinal tract. Clinical and Experimental Pharmacology & Physiology. 2009;36:1041-1048
  15. 15. Challet E. The circadian regulation of food intake. Nature Reviews. Endocrinology. 2019;15:393-405
  16. 16. Polidarová L, Soták M, Sládek M, Pacha J, Sumová A. Temporal gradient in the clock gene and cell-cycle checkpoint kinase Wee1 expression along the gut. Chronobiology International. 2009;26:607-620
  17. 17. Hoogerwerf WA, Sinha M, Conesa A, Luxon BA, Shahinian VB, Cornélissen G. Transcriptional profiling of mRNA expression in the mouse distal colon. Gastroenterology. 2008;135:2019-2029
  18. 18. McClung CA. Mind your rhythms: An important role for circadian genes in neuroprotection. The Journal of Clinical Investigation. 2013;123:4994-4996
  19. 19. Huxley RR, Barzi F, Lam TH, Czernichow S, Fang X, Welborn T, et al. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease. Circulation. 2011;124(19):2056-2064
  20. 20. Hermida RC, Hermida-Ayala RG, Mojón A, Smolensky MH, Fernández JR. Systematic review and quality evaluation of published human ingestion-time trials of blood pressure-lowering medications and their combinations. Chronobiology International. 2021;38(10):1460-1476
  21. 21. Dragoi C.M, Nicolae A.C., Grigore C., Dinu-Pîrvu C.E., Arsene A.L., Characteristics of glucose homeostasis and lipidic profile in a hamster metabolic syndrome model, after the co-administration of melatonin and irbesartan in a multiparticulate pharmaceutical formulation. The Second International Conference on Interdisciplinary Management of Diabetes Mellitus and its Complications, INTERDIAB 2016; 2016.Niculescu, Bucharest: Mar 3-5, pp. 221-229. Diabetes Mellitus as Cardiovascular Disease
  22. 22. Kohsake A, Laposky AD, Ramsey KM, Estrada C, Joshu C, Kobayashi Y, et al. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. Cell Metabolism. 2007;6(5):414-421
  23. 23. Hoogerwerf WA, Hellmich HL, Cornélissen G, Halberg F, Shahinian VB, Bostwick J, et al. Clock gene expression in the murine gastrointestinal tract: Endogenous rhythmicity and effects of a feeding regimen. Gastroenterology. 2007;133(4):1250-1260
  24. 24. Chen Z, Yoo SH, Takahashi JS. Development and therapeutic potential of small-molecule modulators of circadian systems. Annual Review of Pharmacology and Toxicology. 2018;58:231-252
  25. 25. Ahmet I, Wan R, Mattson MP, Lakatta EG, Talan M. Cardioprotection by intermittent fasting in rats. Circulation. 2005;112(20):3115-3121
  26. 26. Bicker J, Alves G, Falcao A, Fortuna A. Timing in drug absoption and disposition: The past, present, and future of chronopharmacokinetics. British Journal of Pharmacology. 2020;177(10):2215-2239
  27. 27. Smolensky MH, Siegel RA, Haus E. Biological rhythms, drug delivery, and chronotherapeutics. In: Siepmann J, Siegel R, Rathbone M, editors. Fundamentals and Applications of Controlled Release Drug Delivery. Advances in Delivery Science and Technology. Boston, MA: Springer; 2012. pp. 359-443
  28. 28. Matsunaga N, Nakamura N, Yoneda N, Qin T, Terazono H, To H. Influence of feeding schedule on 24-h rhythm of hepatotoxicity induced by acetaminophen in mice. The Journal of Pharmacology and Experimental Therapeutics. 2004;311:594-600
  29. 29. Beauchamp D, Guimont C, Grenier L, LeBrun M, Tardif D, Gourde P, et al. Timerestricted feeding schedules modify temporal variation of gentamicin experimental nephrotoxicity. Antimicrobial Agents and Chemotherapy. 1997;41:1468-1474
  30. 30. Ohdo S, Ogawa N, Nakano S, Higuchi S. Influence of feeding schedule on the chronopharmacological aspects of sodium valproate in mice. The Journal of Pharmacology and Experimental Therapeutics. 1996;278:74-81
  31. 31. Yamajuku D, Inagaki T, Haruma T, Okubo S, Kataoka Y, Kobayashi S. Real-time monitoring in three-dimensional hepatocytes reveals that insulin acts as a synchronizer for liver clock. Scientific Reports. 2012;2:439
  32. 32. Oike H, Kobori M, Suzuki T, Ishida N. Caffeine lengthens circadian rhythms in mice. Biochemical and Biophysical Research Communications. 2011;410:654-658
  33. 33. Bowles NP, Thosar SS, Herzig MX, Shea SA. Chronotherapy for hypertension. Current Hypertension Reports. 2018;20:97. DOI: 10.1007/s11906-018-0897-4
  34. 34. Wallach T, Kramer A. Chemical chronobiology: Toward drugs manipulating time. FEBS Letters. 2015;589:1530-1538
  35. 35. Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Archives of Gerontology and Geriatrics. 1997;24:223-231
  36. 36. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, Magalhaes MC, de Lourdes SM, de Bruin VM. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. A randomized, double blind, placebo-controlled study. Journal of Neurology. 2007;254:459-464
  37. 37. Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: A novel therapeutic drug for sleep disorders. CNS Neuroscience & Therapeutics. 2009;15:32-51
  38. 38. Logan RW, McClung CA. Rhythms of life: Circadian disruption and brain disorders across the lifespan. Nature Reviews. Neuroscience. 2019;20:49-65
  39. 39. Radu G, Bordejevic AD, Buda V, Tomescu MC, Dragan I, Dehelean L, et al. Cardiovascular risk factors for different types of psychiatric pathologies: A correlative study. Farmácia. 2020;68:5
  40. 40. Reiter R, Sharma R, Rosales-Corral S, Manucha W, de Almeida Chuffa LG, de Campos Zuccari DAP. Melatonin and pathological cell interactions: Mitochondrial glucose processing in cancer cells. International Journal of Molecular Sciences. 2021;22(22):12494. DOI: 10.3390/ijms222212494
  41. 41. Yokota SI, Horikawa K, Akiyama M, Moriya T, Ebihara S, Komuro G. Inhibitory action of brotizolam on circadian and light-induced per1 and per2 expression in the hamster suprachiasmatic nucleus. British Journal of Pharmacology. 2000;131:1739-1747
  42. 42. Estrada-Reyes R, Valdés-Tovar M, Arrieta-Baez D, Dorantes-Barrón AM, Quero-Chávez D, Solís-Chagoyán H, et al. The timing of melatonin administration is crucial for its antidepressant-like effect in mice. International Journal of Molecular Sciences. 2018;19(8):2278
  43. 43. Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Medicine. 2005;6:459-466
  44. 44. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomiacs. Sleep. 1995;18:598-603
  45. 45. Riemersma-van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ, Van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: A randomized controlled trial. Journal of the American Medical Association. 2008;299:2642-2655
  46. 46. Watanabe A, Hirose M, Kitajima T. A retrospective study of the efficacy of ramelteon for insomnia: Relevance of dose and timing of administration. Sleep and Biological Rhythms. 2018;16:69-75
  47. 47. Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug insight: The use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nature Clinical Practice. Neurology. 2007;3:221-228
  48. 48. Rawashdeh O, Hudson RL, Stepien I, Dubocovich ML. Circadian periods of sensitivity for ramelteon on the onset of running-wheel activity and the peak of suprachiasmatic nucleus neuronal firing rhythms in C3H/HeN mice. Chronobiology International. 2011;28:31-38
  49. 49. Li J, Lu WQ , Beesley S, Loudon AS, Meng QJ. Lithium impacts on the amplitude and period of the molecular circadian clockwork. PLoS One. 2012;7(3):e33292
  50. 50. Barbu CG, Arsene AL, Florea S, Albu A, Sirbu A, Martin S, et al. Cardiovascular risk assessment in osteoporotic patients using osteoprotegerin as a reliable predictive biochemical marker. Molecular Medicine Reports. 2017 Nov;16(5):6059-6067. DOI: 10.3892/mmr.2017.7376
  51. 51. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, BjörklundBodegård K, et al. Prognostic accuracy of day versus night ambulatory blood pressure: A cohort study. Lancet. 2007;370(9594):1219-1229
  52. 52. Diaconu CC, Cozma MA, Dobrică EC, Gheorghe G, Jichitu A, Ionescu VA, et al. Polypharmacy in the management of arterial hypertension—Friend or foe? Medicina. 2021;57:1288
  53. 53. Diaconu CC, Drăgoi CM, Bratu OG, Neagu TP, Pantea Stoian A, Cobelschi PC, et al. New approaches and perspectives for the pharmacological treatment of arterial hypertension. Farmácia. 2018;66(3):408-415
  54. 54. Booth JN, Muntner P, Abdalla M, Diaz KM, Viera AJ, Reynolds K, et al. Differences in night-time and daytime ambulatory blood pressure when diurnal periods are defined by self-report, fixed times, and actigraphy: Improving the detection of hypertension study. Journal of Hypertension. 2016;34(2):235-243
  55. 55. Portaluppi F, Tiseo R, Smolensky MH, Hermida RC, Ayala DE, Fabbian F. Circadian rhythms and cardiovascular health. Sleep Medicine Reviews. 2012;16:151-166
  56. 56. Fares A. Night-time exogenous melatonin administration may be a beneficial treatment for sleeping disorders in beta blocker patients. Journal of Cardiovascular Disease Research. 2011;2(3):153-155
  57. 57. Rodan (Pura) G, Nastasă C, Marc G, Simu H, Oniga O. Evaluation of the efficacy of the association of urapidil with other antihypertensive drugs in the prehospital emergency in Romania. Farmácia. 2019;67:5
  58. 58. Gavrilescu CM, Cernomaz A, Crisan-Dabija R, Popescu RI, Barbu RM, Boisteanu D, et al. A pharmacoepidemiological study on the side effects of indapamide. Farmácia. 2020;68(5):932-939

Written By

Alina Crenguța Nicolae, Ion-Bogdan Dumitrescu, Camelia Cristina Diaconu, Mirela Elena Ritivoiu, Carmen Adella Sirbu and Cristina Manuela Drăgoi

Submitted: 16 March 2022 Reviewed: 04 August 2022 Published: 30 August 2022